6533b873fe1ef96bd12d59ad

RESEARCH PRODUCT

“Preemptive” Live Donor Liver Transplantation for Fibrolamellar Hepatocellular Carcinoma: A Case Report

Klaus J. SchmitzIoannis FouzasM. MalagóHauke LangC. E. BroelschSusanne BeckebaumGeorgios C. SotiropoulosErnesto P. Molmenti

subject

Adultmedicine.medical_specialtyCarcinoma HepatocellularLive donormedicine.medical_treatmentMedizinLiver transplantationInferior vena cavaGastroenterologyInternal medicineLiving DonorsmedicineHumansYoung adultneoplasmsTransplantationbusiness.industryLiver NeoplasmsFactor VCancermedicine.diseaseCombined Modality Therapydigestive system diseasesSurgeryRadiographyFibrolamellar hepatocellular carcinomamedicine.veinHepatocellular carcinomaMutationFemaleSurgerySafetyLiver cancerbusiness

description

Fibrolamellar (FL) hepatocellular carcinoma (HCC) is a distinctive form of primary HCC that occurs principally in children and young adults. Although liver transplantation is not contraindicated for FL-HCC, noncirrhotic patients with large HCC tumors (including FL-HCCs) are not prioritized. Although hepatic resection is considered to be the primary treatment for FL-HCC, living donor liver transplantation is evolving into a potentially better alternative. Herein we have reported successful "preemptive" living donor liver transplantation for presumed recurrence of FL-HCC after an extended right hepatectomy with resection and synthetic graft replacement of the inferior vena cava.

yearjournalcountryeditionlanguage
2008-12-01Transplantation Proceedings
https://doi.org/10.1016/j.transproceed.2008.09.050